Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Erdafitinib - Janssen Pharmaceutica

Next Previous
Drug Profile

Erdafitinib - Janssen Pharmaceutica

Alternative Names: BALVERSA; Barbasa; Barbaza; G-024; JNJ-42756493; JNJ-493; TAR-210

Latest Information Update: 28 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Astex Therapeutics; Newcastle University
  • Developer Genentech; Janssen Pharmaceutica; Janssen Research & Development; Multiple Myeloma Research Consortium; National Cancer Institute (USA); University Health Network of Toronto; University of Washington; Vanderbilt-Ingram Cancer Center
  • Class Antineoplastics; Diamines; Pyrazoles; Quinoxalines; Small molecules
  • Mechanism of Action Fibroblast growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Urogenital cancer
  • Phase III Bladder cancer
  • Phase II Cholangiocarcinoma; Gastric cancer; Multiple myeloma; Non-small cell lung cancer; Oesophageal cancer; Prostate cancer; Solid tumours
  • Phase I/II Liver cancer
  • No development reported Breast cancer; Lymphoma

Most Recent Events

  • 28 May 2025 No recent reports of development identified for phase-I development in Bladder-cancer in Germany (Intravesicular)
  • 28 May 2025 No recent reports of development identified for phase-I development in Bladder-cancer in Netherlands (Intravesicular)
  • 28 May 2025 No recent reports of development identified for phase-I development in Bladder-cancer in South Korea (Intravesicular)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top